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HAL-treated patients that had responded to therapy at
each of the three thresholds defined. Six-week response-
curves were compared using log-rank tests.
RESULTS: As the threshold for classifying a patient as a
responder increased, the relative divergence between
drug-response curves increased with the OLZ treatment
group consistently attaining higher proportions of re-
sponders than the HAL treatment group. At a minimal
threshold for response (20%), 77% of OLZ versus
70% of HAL-treated patients responded by week 6 (p 
0.002). At a high bar threshold for response (65%),
25.9% of OLZ versus 15.6% of HAL-treated patients re-
sponded by week 6 (p  .001). Furthermore, a separation
of response rates in favor of OLZ could be seen as early
as week 2.
CONCLUSION: Rigorously as compared to minimally de-
fined thresholds for response clearly differentiate the greater
likelihood of patients achieving superior improvement on
the novel antipsychotic OLZ as compared to HAL.
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IMPROVEMENT IN QUALITY OF LIFE AND 
DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIC 
PATIENTS IS ASSOCIATED WITH ROBUST 
ACUTE TREATMENT RESPONSE OF 
OLANZAPINE VERSUS HALOPERIDOL
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OBJECTIVE: The objective of this analysis was to ex-
plore the association of improvement in QoL and depres-
sive symptoms with robust acute treatment response of
olanzapine (OLZ) versus haloperidol (HAL).
METHODS: Data was analyzed post-hoc from a double-
blind, randomized (OLZ versus HAL), trial of 1996 pa-
tients with schizophrenia or a related disorder. The treat-
ment response was classified into four groups based on
improvement of the Brief Psychiatric Rating Scale (BPRS)
total scores at 6 weeks: 20%, 20–40%, 40–65% and
65% improvement. Mean percent changes of Quality
of Life Scale (QLS) scores and Montgomery-Asberg De-
pression Rating Scale (MADRS) were determined.
RESULTS: There was a significant positive association
between the more robust level of response (i.e., 65%)
and improvements in depressive symptoms and QLS
across treatment groups. Patients treated with OLZ
started to access moderate improvement (10% im-
provement) in QLS once they attained a 20% or greater
improvement in BPRS while for the HAL-treated pa-
tients, only those who had a 65% or greater response in
BPRS could exceed moderate QLS improvement. The
mean percent change in QLS in the 20–40% BPRS re-
sponse group was 13.4% for OLZ versus 1% for HAL (p 
0.031) and in the 65% or greater BPRS response group
was 41.8% for OLZ versus 32.8% for HAL (p  0.45).
Similar observations were demonstrated in improvement
on the MADRS. For patients with a 40–65% BPRS re-
sponse, the improvement in MADRS was 34.9% for
OLZ versus 6.7% for HAL (p  0.027).
CONCLUSION: A more robust categorical acute treat-
ment response resulted in greater improvement in QoL
and depressive symptoms across treatment groups. For pa-
tients attaining the same level of acute treatment response
though, there may be significantly greater improvements in
QoL and depressive symptoms enjoyed by OLZ-treated
patients compared to those treated with HAL.
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OBJECTIVE: Patients with schizophrenia switched from
conventional antipsychotics, olanzapine, or risperidone,
to ziprasidone show significant improvements in weight,
prolactin levels, and lipid profile. Since such benefits may
affect patient behavior and resource use, Drug Attitude
Inventory (DAI) was administered to assess attitudes/feel-
ings about antipsychotic therapy.
METHODS: Three six-week multi-center, open-label,
parallel-group trials of similar design were undertaken in
stable schizophrenic outpatients switched from conven-
tional antipsychotics (n  108), olanzapine (n  104), or
risperidone (n  58) because of poor tolerability or insuf-
ficient efficacy. Each trial randomized patients to 1 of 3
switch strategies—“slow” taper, “fast” taper, or “abrupt
discontinuation” of prior medication before initiating
ziprasidone (80 mg/day for 2 days; 40–160 mg/day there-
after). The 10-question true/false DAI was administered
at baseline and week six. The primary summary measure
was total score (sum of responses to all questions). Data
were combined from all switch subsets for each study be-
cause there was no significant difference in mean change
from baseline to week six among strategies. Positive total
score indicated likely compliance, whereas negative total
score, likely noncompliance. A categorical linear model
was used to analyze marginal probabilities of favorable
responses over total, attitudinal, and subjective question
sets.
RESULTS: Total DAI scores improved significantly in
patients switched to ziprasidone from conventionals (P 
.003) or risperidone (P  .008). Categorical analysis
identified significant improvements in patients switched
to ziprasidone from conventionals (P  .05 all items, P 
.02 subjective) and a trend toward improved scores in
those switched from olanzapine (P  .06 for both). DAI
improvement from baseline to week six was consistently
driven by positive change in subjective feelings. Ziprasi-
done was safe, well-tolerated, and effective, regardless of
dose or switch strategy.
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CONCLUSIONS: Schizophrenic outpatients report better
subjective feelings about medication use after switching to
ziprasidone. These findings have implications for greater
patient compliance with ziprasidone and, possibly, for de-
creased relapse rates and health-care resource use.
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OBJECTIVE: The purpose of this analysis was to de-
scribe and compare patterns of drug selection, dosing,
and utilization among depressed patients treated with
SSRIs (citalopram, fluoxetine, paroxetine, and sertraline)
and venlafaxine in US managed care.
METHODS: Symmetry Health Data Systems’ Episode
Treatment Group methodology was applied to PharMet-
rics’ Integrated Outcomes Database to identify adult sub-
jects (18 years.) diagnosed with depressive disorder and
treated with one of the study medications between Janu-
ary 1, 1998 and June 30, 1999. Prescription claims
records were used to identify patterns of drug selection,
dosing, and utilization (medication persistence, augmen-
tation, switching, and time to change) for each medica-
tion cohort. Descriptive statistics were used to character-
ize drug selection and dosing patterns, and parametric
and nonparametric methods (ANOVA and chi-square)
were used to compare utilization indicators across study
groups.
RESULTS: Twelve thousand twenty six patients met in-
clusion criteria. The study cohorts were demographically
similar. Index antidepressant drug prescriptions were for
citalopram (6.2%), fluoxetine (24.6%), paroxetine (29.5%),
sertraline (33.4%), and venlafaxine (6.2%). Citalopram pa-
tients more often started (86.7%) and ended (78.4%) on the
lowest available dose. Each cohort showed similar patterns
of dosage titration/adjustment. The mean number of pre-
scriptions was similar across cohorts; citalopram-treated
patients had a significantly higher rate of persistence
(mean  118.3 days) than those treated with paroxetine
(106.5), sertraline (108.8), and venlafaxine (108.2) cohorts
(p  .001). Augmentation and switching rates were similar
across cohorts; citalopram patients whose therapy changed
had a significantly longer time to change (mean  80.9
days) than fluoxetine (76.8 days, p  0.02), paroxetine
(72.1 days, p .001), sertraline (69.6 days, p  .001), or
venlafaxine (66.8 days, p  .001) patients.
CONCLUSIONS: Of the antidepressants evaluated, cit-
alopram was most frequently prescribed at the lowest
available dose. Persistence rates were also highest with
citalopram. Clinicians and payers should consider differ-
ences in dosing and persistence to provide optimal care
and benefits for depressed patients.
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OBJECTIVE: Psychiatrists often see patients who show
only a partial response to conventional antipsychotics.
This study assessed the cost-effectiveness and economic
impact of quetiapine treatment in this clinically impor-
tant patient population.
METHODS: A decision-analytic model with Markov
processes was constructed to assess the costs and health
benefits of quetiapine and haloperidol treatment over a
five-year period in a UK National Health Service (NHS)
setting. Response to medication and incidence of extra
pyramidal symptoms (EPS), were derived from a prospec-
tive, double blind, randomized clinical trial, the PRIZE
study. Transition probabilities used in the model were de-
rived from a thorough review of the literature and expert
opinion. Resource use unit costs were taken from the lit-
erature. Discount rates of 6% were applied to costs and
1.5% to outcomes as recommended in the UK by the Na-
tional Institute of Clinical Excellence.
RESULTS: This model found the overall cost of quetia-
pine treatment per patient to be comparable with the cost
of treatment with haloperidol over a five-year period
(£37,379 quetiapine versus £37,596 haloperidol). Hospi-
talization and institutionalization costs were £1,911 less
with quetiapine. Outpatient cost savings was estimated at
£642 with quetiapine per five years. Over the five-year
course of the model, the short-term clinical benefits
shown in the PRIZE study lead to quetiapine-treated pa-
tients experiencing fewer relapses and responding to
treatment for a longer time compared to haloperidol-
treated patients. Sensitivity analyses showed the results to
be robust to testing of key assumptions.
CONCLUSIONS: With better outcomes and similar treat-
ment costs to haloperidol, quetiapine represents a cost-
effective treatment for schizophrenia in patients who show
only a partial response to conventional antipsychotics.
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OBJECTIVE: The purpose of this analysis was to de-
scribe and compare patterns of comorbidities and copre-
scribing among depressed patients treated with SSRIs
